The Cancer Drug Parity Act of 2025 adds a new Section 726 to ERISA that requires group health plans, and health insurance offered in connection with those plans, to ensure cost‑sharing for FDA‑approved, patient‑administered oral anticancer drugs is no less favorable than cost‑sharing for intravenously administered or injected anticancer medications provided by a clinician. The statute defines cost‑sharing to include deductibles, coinsurance, copayments, and caps on those out‑of‑pocket amounts.
The bill limits the requirement to drugs prescribed when the treating physician finds them medically necessary or clinically appropriate, bars plan redesigns intended to evade parity (for example, reclassifying benefits or increasing out‑of‑pocket costs), preserves legitimate utilization controls such as prior authorization, and defers to state laws that offer stronger protections. It becomes effective for plan years beginning on or after January 1, 2026 and directs the GAO to study the law’s impact within two years of enactment.
At a Glance
What It Does
The bill mandates parity in patient cost‑sharing between oral, patient‑administered anticancer drugs and clinician‑administered anticancer drugs for ERISA group health plans and related insured coverage. It prohibits benefit redesigns intended to increase members’ out‑of‑pocket costs for oral anticancer medications as a means of compliance avoidance.
Who It Affects
The rule applies to ERISA‑governed group health plans (including self‑insured employer plans) and health insurance coverage offered in connection with those plans; health insurers that issue group coverage; employers who sponsor plans; and patients receiving oral anticancer therapies. Pharmacy benefit managers, specialty pharmacies, and plan administrators will have operational roles in implementation.
Why It Matters
It tackles a long‑standing source of patient cost disparity between oral and infused cancer treatments and could change plan benefit design, PBM contracting, and employer health costs. The GAO study requirement ensures Congress will receive data on cost and access impacts, which may prompt follow‑on regulatory or legislative action.
More articles like this one.
A weekly email with all the latest developments on this topic.
What This Bill Actually Does
The bill inserts a new Section 726 into ERISA. Under subsection (a) a group health plan (and any insurance sold in connection with it) that covers anticancer drugs administered by clinicians must ensure that patient cost‑sharing for FDA‑approved oral anticancer medications is at least as favorable as the cost‑sharing for clinician‑administered anticancer drugs.
The statute uses straightforward language—'no less favorable'—and explicitly lists the forms of cost‑sharing (deductibles, coinsurance, copayments, and caps) that the parity obligation covers.
Subsection (b) narrows the mandate to clinically prescribed drugs: the oral medication must be prescribed because the treating physician finds it medically necessary to kill, slow, or prevent cancer cell growth or clinically appropriate in terms of type, frequency, extent, site, and duration. That ties coverage to a treating clinician’s judgment rather than an automatic entitlement for every FDA‑approved oral agent.To prevent simple workarounds, subsection (c) bars plans from complying by redesigning benefits in ways that increase out‑of‑pocket costs, reclassify benefits, or impose stricter limits on oral agents than on intravenous or injected drugs.
Subsection (d) clarifies that the law does not force substitution of therapies, does not block reasonable utilization controls (for example, prior authorization), and does not preempt state laws that provide greater protections. The bill becomes effective for plan years beginning on or after January 1, 2026.Finally, the statute tasks the Government Accountability Office with a study due within two years of enactment comparing out‑of‑pocket costs and access in plans subject to the new rule versus plans that are not, and requires a report to Congress with recommendations.
That creates a data feedback loop likely to influence future rulemaking or legislation but also means key impact metrics may not be available immediately upon implementation.
The Five Things You Need to Know
The bill requires group health plans and health insurance offered in connection with those plans to make cost‑sharing for FDA‑approved, patient‑administered oral anticancer drugs no less favorable than cost‑sharing for intravenously administered or injected anticancer drugs.
Cost‑sharing is explicitly defined to include deductibles, coinsurance, copayments, and any maximum limitation on those out‑of‑pocket amounts.
The parity mandate applies only when the treating physician prescribes the oral anticancer medication as medically necessary or clinically appropriate (including type, frequency, extent, site, and duration).
Plans may not satisfy parity by redesigning or replacing benefits in ways that increase out‑of‑pocket costs, reclassify benefits to shift cost burden, or impose more restrictive limits on oral anticancer medicines than on provider‑administered therapies.
The requirement starts for plan years beginning on or after January 1, 2026, and the GAO must complete a study within two years of enactment assessing effects on out‑of‑pocket costs and access and submit recommendations to Congress.
Section-by-Section Breakdown
Every bill we cover gets an analysis of its key sections.
Short title
Designates the statute as the 'Cancer Drug Parity Act of 2025.' This is a captionary provision only but signals congressional intent to target cost parity between oral and provider‑administered anticancer therapies.
Parity requirement for oral anticancer drugs
Creates the substantive obligation: if a plan covers anticancer medications administered by a health care provider, it must offer patient cost‑sharing for FDA‑approved, patient‑administered oral anticancer drugs that is no less favorable. Practically, plans will need to audit current benefit tables, copay tiers, and coinsurance schedules and adjust pharmacy benefit design or medical benefit linkage to ensure parity across administration routes.
Clinical prescription limitation
Limits coverage parity to oral anticancer medications prescribed after a treating physician finds the drug medically necessary or clinically appropriate. This inserts a clinician‑centered gate: plans can reference treating‑physician determinations in coverage decisions, which preserves medical judgment but raises questions about documentation standards and appeals processes.
Anti‑evasion rules and retained plan controls
Subsection (c) bars plans from achieving compliance by restructuring benefits to shift costs onto enrollees (for example, moving an oral drug into a pharmacy tier with higher copays while lowering other benefits). Subsection (d) makes two practical concessions: it does not require substituting oral for other therapies and it allows plans to use standard utilization management tools such as prior authorization. It also preserves any state laws that provide stronger protections, creating a federal baseline rather than preemption of more protective state standards.
Definition of cost‑sharing
Defines 'cost‑sharing' to include deductibles, coinsurance, copayments, and caps on these out‑of‑pocket expenses. That explicit definition narrows interpretive disputes about whether certain cost elements—such as specialty drug coinsurance or benefit maximums—fall within the parity obligation and will be central in compliance testing and audits.
GAO study, report, and effective date
Sets the effective date for plan years beginning on or after January 1, 2026 and directs the GAO to complete a comparative study within two years of enactment on out‑of‑pocket costs and access, with recommendations for Congress. The study requirement creates an evidence base for further policy action but also means empirical assessment will lag initial implementation.
This bill is one of many.
Codify tracks hundreds of bills on Healthcare across all five countries.
Explore Healthcare in Codify Search →Who Benefits and Who Bears the Cost
Every bill creates winners and losers. Here's who stands to gain and who bears the cost.
Who Benefits
- Patients taking FDA‑approved oral anticancer medications — they stand to gain through lower or equal out‑of‑pocket costs versus infused therapies, which can reduce financial toxicity and improve adherence.
- Treating clinicians (oncologists and prescribing physicians) — parity reduces administrative friction when prescribing oral options and supports treatment decisions grounded in clinical appropriateness rather than patient cost barriers.
- Insured employees and dependents enrolled in ERISA group plans — members of self‑insured employer plans may see fewer coverage denials or higher cost burdens shifted to oral therapy users.
- Advocacy organizations and patient navigators — parity simplifies benefit counseling and the casework required to secure affordable oral cancer therapy for patients.
Who Bears the Cost
- Plan sponsors, especially employers that self‑insure — they may face higher pharmacy spend or administrative costs to restructure benefits and absorb the difference if oral drugs previously carried higher member cost‑sharing.
- Health insurers offering group coverage — issuers will need to redesign plan documents, update formulary and tiering policies, and potentially renegotiate PBM contracts to meet parity requirements.
- Pharmacy benefit managers and specialty pharmacies — PBMs may need to alter benefit integration, prior authorization workflows, and reimbursement models; specialty pharmacies may see changes in dispensing patterns and revenue mixes.
- Plan administrators and HR/compliance teams — they must implement, monitor, and document parity compliance, update plan summaries, and manage member inquiries and appeals, increasing operational workload.
Key Issues
The Core Tension
The bill pits patient access and financial protection for people prescribed oral anticancer drugs against plans’ and employers’ need to control costs and preserve administrability; achieving literal 'parity' is administratively and actuarially complex, and the measures that guarantee equal out‑of‑pocket exposure can increase premiums or shift costs elsewhere, creating a trade‑off between individual affordability and collective cost containment.
The bill attempts a surgical fix—targeting an identified disparity between oral and clinician‑administered anticancer therapies—but raises practical implementation questions. 'No less favorable' is a strong standard but legally indeterminate: it requires plan actuaries and compliance teams to map medical and pharmacy benefits against each other and make judgment calls about equivalency (e.g., is a lower coinsurance but higher deductible 'no less favorable'?). The explicit inclusion of caps helps, but many modern plans use complex tiering, specialty coinsurance, and accumulators that complicate straightforward comparisons.
Enforcement mechanisms are not specified in the text. The statute creates obligations under ERISA, which means remedies and enforcement will likely flow through ERISA’s civil enforcement regime and state regulation of insurers for insured plans, but the bill does not add a private right of action or a federal enforcement pathway beyond existing ERISA remedies.
That gap could slow dispute resolution and create uneven outcomes. Moreover, allowing utilization controls like prior authorization preserves clinical oversight but may substitute one form of barrier (cost) for another (administrative access hurdles) unless regulators and payers streamline medical necessity protocols.
Finally, while the GAO study will provide empirical evidence, its two‑year timeframe means policymakers and stakeholders will have to manage implementation without a comprehensive national impact assessment in the near term.
Try it yourself.
Ask a question in plain English, or pick a topic below. Results in seconds.